Skip to content
GLOBALANCE INTELLIGENCEThe economy ahead.
This Week Index 28/100 Sign in
Money & Investments › GI 100 Index
The Great Value ShiftInvestment ThemesGI 100 IndexGI PortfolioStart Future Check
AI FOOTPRINTlimitedASSESSMENT 2026GLOBALANCEINTELLIGENCE
Globalance AI Footprint

Assessment as of November 2026 · next assessment 2027.

Result of the assessment by the Globalance research team under the published methodology. Not a certification or quality label.

How we assess ›

How this rating is builtVideo · 0:52
GI 100 Index · Profile

Amgen Inc

USAAdoptersAssignment FullData quality Low

Key messagelimited AI Footprint

Amgen has assigned oversight of artificial intelligence to a board committee and an internal expert council and describes an extensive programme to protect its IT systems, but publishes no binding rules on how AI applications are tested and approved. The company discloses little about the limits of individual AI applications, and in July 2026 patient data was stolen in an attack on cloud storage, although a link to AI is not established.

Opportunities

  • Safetysolid

    The 10-K describes a concrete cybersecurity programme with a CISO, a governance council, integration into enterprise risk management, reviews by internal audit, a biennial external maturity assessment and a supplier risk process; it also documents that two hires with false identities were detected …

    The 10-K describes a concrete cybersecurity programme with a CISO, a governance council, integration into enterprise risk management, reviews by internal audit, a biennial external maturity assessment and a supplier risk process; it also documents that two hires with false identities were detected before any data was exfiltrated (S01). The counter-evidence is the material incident of July 2026, in which patient data was stolen from third-party cloud environments (S07, S08) and a class action is pending (S22); a link to AI systems is not established, hence a medium controversy and a deduction within “solid” instead of a cap. On the reliability of individual AI applications (ATOMIC, Eva, visual inspection) there is only company and secondary information (S15, S16, S18); no findings by the FDA or EMA on Amgen's AI were found.

Risks

  • Responsibilitylimited

    AI-specific oversight is documented in mandatory filings: the board committee CRCC oversees information systems and security including AI, the Audit Committee the use of AI in financial systems (S03, S04), and a cross-functional AI Governance Council sponsored by the Chief Compliance Officer and …

    AI-specific oversight is documented in mandatory filings: the board committee CRCC oversees information systems and security including AI, the Audit Committee the use of AI in financial systems (S03, S04), and a cross-functional AI Governance Council sponsored by the Chief Compliance Officer and the SVP AI & Data steers the introduction of third-party AI services (S01); the leadership roles were newly assigned from 2026-06-01 (S31). However, there is no company-published AI policy with operational content and no described approval, risk classification or review procedure backed by grade A or B evidence: the 10-K mentions only guardrails without a procedure (S01), the rules in the code of conduct and the NIST principles are documented only at grade C (S09, S11), and risk classes, metrics and an external review of the AI programme are not published. Under the minimum requirement for “solid”, the pillar is therefore “limited” on the basis of principles, without a documented material weakness.

  • Transparencylimited

    Amgen describes AI use cases and principles publicly (S09, S14, S15, S16) and names AI risks in general terms in the 10-K (S01), but discloses no performance limits, error rates or model information for any of its own systems.

    Amgen describes AI use cases and principles publicly (S09, S14, S15, S16) and names AI risks in general terms in the 10-K (S01), but discloses no performance limits, error rates or model information for any of its own systems. Labelling is documented only for the agent Eva towards insurers (S16, company statement); whether patients are informed remains open. The transparency information therefore rests on grade C evidence.

  • Risk area

    AI in drug safety, manufacturing and quality inspection

  • Risk area

    AI in clinical trials and regulatory submissions

  • No serious controversy recorded.

What lies behind the assessment

Research of 3 November 2026
43searches
35pages and documents read
10primary documents
2controversies checked
6open points, named openly
The full research: pillars, evidence, controversies and open points
AI Footprint · Adopter · As of 3 November 2026
Amgen IncOverall rating: limited

Amgen has assigned AI oversight to a board committee and an internal council and describes an extensive cyber programme. Amgen does not disclose binding, documented rules for testing and approving AI applications.

Responsibility

40 %
limitedsolidstrong

A committee and a council are responsible for AI, but documented approval rules are missing.

  • +A board committee oversees AI and cybersecurity Source ↗
  • +AI Governance Council steers the introduction of third-party AI services Source ↗
  • +Code of conduct requires final human decision Source ↗
  • –No risk classes and no approval process published Source ↗
  • –No metrics and no external review of the AI programme
All sources for this pillar (12)

Safety

40 %
limitedsolidstrong

The cyber programme is described concretely, but in 2026 patient data was stolen from cloud storage.

  • +Cyber programme with CISO, internal audit and external maturity review Source ↗
  • +Two hires with false identities detected in time Source ↗
  • –Patient data stolen from third-party cloud environments in 2026 Source ↗
  • –Class action for negligence over the data incident pending Source ↗
  • –No test results for ATOMIC, Eva or visual inspection Source ↗
All sources for this pillar (11)

Transparency

20 %
limitedsolidstrong

Use cases are described, but limits, error rates and model information are missing.

  • +AI use cases and principles described publicly Source ↗
  • +Agent Eva identifies itself to insurers as automated Source ↗
  • –No limits or error rates of in-house systems published Source ↗
  • –No model or system documentation for ATOMIC and SAGE
  • –Privacy statement without statements on AI Source ↗
All sources for this pillar (9)
What is missing for “strong”

These steps are in the company’s own hands.

1Responsibility
Disclose risk classes and approvals

Publish risk classes, approval procedures and metrics of the AI programme and have the programme externally reviewed.

2Safety
Document testing of AI applications

Disclose validation and monitoring reports on SAGE, ATOMIC and visual inspection and the cause of the 2026 data incident.

3Transparency
Publish the limits of the systems

Document limits, error rates and data provenance for in-house AI systems and inform patients about the use of AI.

Context: 101 companies assessed

Distribution of overall ratings, no ranking
strong
none yet
solid
limited
← Amgen Inc is one of 66

No company reaches “strong” today. Disclosure on how companies handle AI is still young across the market.

Controversies
2 1 medium, 1 minor

No deduction for controversies.

Largest risk area
AI errors in drug safety and manufacturing

Amgen is developing AI to assess safety signals and uses it in visual inspection, but discloses no validation reports, limits or error rates.

How thoroughly assessed
32 Evidence

10 primary documents read, 43 searches.

Read the full reasoning and all sources
Amgen Inc · Full reasoning

Board oversight of AI and a cyber programme, but no published approval rules

Overall rating “limited”. No deduction for controversies. The superscript numbers link directly to the source.

1 · Responsibility

limitedWeight 40%

Amgen documents board oversight of AI and an AI Governance Council, but publishes no documented AI policy and no approval procedure.

What is documented
  • The Corporate Responsibility and Compliance Committee oversees information systems and security including AI and cybersecurity2 3
  • The Audit Committee oversees financial systems including their use of AI2 3
  • An AI Governance Council sponsored by the Chief Compliance Officer and the SVP AI & Data steers purchased AI services with guardrails and training1
  • Since 2026-06-01 an EVP for research, AI and data and an SVP Chief Technology Officer have been in place4 5
  • The code of conduct permits only approved AI tools and requires human judgement in decisions on patient safety and regulatory matters7
The case against
Risk management only as a principle
  • Amgen commits to the NIST characteristics of trustworthy AI but publishes no risk classes and no approval process6
  • No AI inventory is published
  • The content and frequency of AI reports to the committee are not disclosed2
Missing accountability
  • There are no AI metrics, no certification and no external review of the AI programme
  • A dedicated AI complaints channel with documented remediation is missing; there is only the general Business Conduct Hotline7 12
Sources for Responsibility (12)
  1. Amgen Inc. (SEC EDGAR): Form 10-K for the fiscal year ended December 31, 2025 · 31 December 2025 · primary source
  2. Amgen Inc. (SEC EDGAR): Definitive Proxy Statement (DEF 14A) 2026, Annual Meeting 2026-05-19 · 19 May 2026 · primary source
  3. Amgen Inc. (SEC EDGAR): Definitive Proxy Statement (DEF 14A) 2025 · 23 May 2025 · primary source
  4. Amgen Inc.: Amgen Announces Retirement of David M. Reese, Executive Vice President and Chief Technology Officer · 22 April 2026 · primary source
  5. Amgen Inc.: Sean Bruich – Senior Vice President and Chief Technology Officer · 3 November 2026 · secondary source
  6. Amgen Inc.: Artificial Intelligence Vision · 3 November 2026 · secondary source
  7. Amgen Inc.: Serving Patients with Integrity: Amgen's Global Code of Conduct (©2026) · 3 November 2026 · secondary source
  8. Amgen Inc.: How Amgen Uses AI to Support Patient Access & Reimbursement · 18 November 2025 · secondary source
  9. Amgen Inc. (Karriereseite): Senior Manager, Responsible AI Governance (job advertisement) · 28 August 2026 · secondary source
  10. Amgen Inc.: Cybersecurity and Data Privacy (Healthy Amgen) · 3 November 2026 · secondary source
  11. Amgen Inc.: Amgen Binding Corporate Rules · 3 November 2026 · secondary source
  12. Amgen Inc.: Code of Conduct (website) · 3 November 2026 · secondary source

2 · Safety

solidWeight 40%

Amgen describes a concrete cyber programme with external review, but a material data incident in 2026 and missing test reports on AI applications stand against this.

What is documented
  • The 10-K describes a CISO, a governance council, reviews by internal audit and a biennial external maturity assessment1
  • Two hires with false identities were detected and terminated before data was exfiltrated or malware installed1
  • In the July 2026 incident, the response plan, containment and external forensics were applied and the incident was reported via 8-K5
  • According to Amgen, trained staff review all AI responses of the agent Eva; tests for bias are ongoing3
  • Amgen is a member of H-ISAC and trains employees annually on cybersecurity7
The case against
Data incidents
  • In July 2026 unauthorised parties stole protected health data from third-party cloud environments; a link to AI is not established5 6
  • According to the lawsuit, Amgen acted negligently; the case Humphreys v. Amgen is pending11
  • Data on Amgen personnel was taken at the service provider Sirva; according to the notice, Amgen's own systems were not affected8
Missing testing of AI applications
  • For ATOMIC, Eva and visual inspection there is only company and secondary information, no test results and no red-teaming2 3 4
  • No findings by the FDA or EMA on Amgen's use of AI were found
Sources for Safety (11)
  1. Amgen Inc. (SEC EDGAR): Form 10-K for the fiscal year ended December 31, 2025 · 31 December 2025 · primary source
  2. Amgen Inc.: Follow the Data (ATOMIC) · 17 April 2025 · secondary source
  3. Amgen Inc.: How Amgen Uses AI to Support Patient Access & Reimbursement · 18 November 2025 · secondary source
  4. Bio-IT World: Amgen's AI Futures: Digital Twins, Unstructured Data, Human Review · 3 September 2024 · secondary source
  5. Amgen Inc. (SEC EDGAR): Form 8-K, Item 1.05 Material Cybersecurity Incidents · 31 July 2026 · primary source
  6. Amgen Inc. (SEC EDGAR): Form 10-Q for the quarterly period ended June 30, 2026 · 30 June 2026 · primary source
  7. Amgen Inc.: Cybersecurity and Data Privacy (Healthy Amgen) · 3 November 2026 · secondary source
  8. ClassAction.org: Amgen Inc. Data Breach (September 2024) – Sirva Relocation · 8 August 2024 · secondary source
  9. ClaimDepot: Amgen Reports Data Breach Exposes Protected Health Info · 3 August 2026 · secondary source
  10. Amgen Inc.: Serving Patients with Integrity: Amgen's Global Code of Conduct (©2026) · 3 November 2026 · secondary source
  11. U.S. District Court, Central District of California (via Courthouse News): Complaint, Humphreys v. Amgen Inc., No. 2:26-cv-08688 · 6 August 2026 · primary source

3 · Transparency

limitedWeight 20%

Amgen describes AI applications and principles publicly, but discloses no limits, error rates or model information for any of its own systems.

What is documented
  • Amgen publicly describes AI applications in research, trials, patient access and office work2 3 4 5
  • The 10-K names risks from AI-based systems and faulty AI outputs1
  • The agent Eva identifies itself to insurers as an automated system and immediately offers a human4
  • Amgen commits to explainability as one of the NIST characteristics of trustworthy AI7
The case against
Missing system information
  • Results for ATOMIC are published without methodology; limits of individual systems are not stated3
  • There are no model or system cards for in-house models such as ATOMIC, SAGE or generative biology
  • Information on consent and governance is missing for the genomic data used for the Freyja computer9
Informing those affected
  • Whether patients are informed about the use of AI is not documented
  • The privacy statement contains no statements on AI or chatbots6
Sources for Transparency (9)
  1. Amgen Inc. (SEC EDGAR): Form 10-K for the fiscal year ended December 31, 2025 · 31 December 2025 · primary source
  2. Amgen Inc.: Generative AI Tools Support Amgen's Mission to Serve Patients · 7 August 2025 · secondary source
  3. Amgen Inc.: Follow the Data (ATOMIC) · 17 April 2025 · secondary source
  4. Amgen Inc.: How Amgen Uses AI to Support Patient Access & Reimbursement · 18 November 2025 · secondary source
  5. Amgen Inc.: From the Office to the Lab, Amgen Uses AI Tools to Unlock Innovation · 22 May 2024 · secondary source
  6. Amgen Inc.: Privacy Statement (Last Updated December 11, 2024) · 11 December 2024 · secondary source
  7. Amgen Inc.: Artificial Intelligence Vision · 3 November 2026 · secondary source
  8. Amgen Inc.: Serving Patients with Integrity: Amgen's Global Code of Conduct (©2026) · 3 November 2026 · secondary source
  9. NVIDIA: Amgen to Build Generative AI Models for Novel Human Data Insights and Drug Discovery · 8 January 2024 · secondary source

4 · Why the harm rule does not apply

The harm rule does not apply: within the 36-month window there is no judgment, regulatory decision or fine concerning harm caused by Amgen's AI. The 2026 data incident has no established link to AI.

5 · Controversies (2)

6 · What remains open

  • Outcome of the forensic investigation and cause of the 2026 cloud incident; officially confirmed number of people affected
  • Findings by the FDA or EMA on Amgen's AI applications
  • Risk classes, approval procedures and metrics of the AI programme
  • Information provided to patients about the use of AI
  • The 2024 and 2025 sustainability reports could not be retrieved regularly and do not count as evidence
  • Contradiction in the company's statements on human review in patient access

7 · How it was assessed

Cut-off date: 3 November 2026 · 43 searches, 35 fetches.

Primary documents read (10)
  • Form 10-K FY2025 (Items 1, 1A, 1C)
  • Proxy Statement 2026 (complete) and 2025 (up to 100,000 characters)
  • Form 8-K Item 1.05 dated 2026-07-31
  • Form 8-K Voting Results 2024 and 2025
  • Form 10-Q Q2 2026 (Risk Factors)
  • Klageschrift Humphreys v. Amgen Inc., No. 2:26-cv-08688 (C.D. Cal.)
  • Artificial Intelligence Vision
  • Global Code of Conduct (©2026)
  • Cybersecurity and Data Privacy, Privacy Statement, Binding Corporate Rules
  • Press Release: CTO Leadership Change dated 2026-04-22

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0

We assess documented practice in dealing with AI; this is not an investment recommendation. Three pillars, weights 40/40/20, harm rule.

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0. Documented observations from public sources, no investment recommendation.

Important Notice. This material is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any financial instrument, nor does it constitute investment advice or a recommendation. The GI 100 Index is a rules-based strategy index of Globalance Bank. Investments involve risk, including the loss of capital invested. The final product documents (including FinSA) shall prevail in all cases.

Your company? Information on inclusion in the GI 100 Index →

What comes next